JP2017502941A5 - - Google Patents

Download PDF

Info

Publication number
JP2017502941A5
JP2017502941A5 JP2016538536A JP2016538536A JP2017502941A5 JP 2017502941 A5 JP2017502941 A5 JP 2017502941A5 JP 2016538536 A JP2016538536 A JP 2016538536A JP 2016538536 A JP2016538536 A JP 2016538536A JP 2017502941 A5 JP2017502941 A5 JP 2017502941A5
Authority
JP
Japan
Prior art keywords
capsule
drug substance
weight
pharmaceutical formulation
total weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016538536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502941A (ja
JP6522619B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/066820 external-priority patent/WO2015087283A1/en
Publication of JP2017502941A publication Critical patent/JP2017502941A/ja
Publication of JP2017502941A5 publication Critical patent/JP2017502941A5/ja
Application granted granted Critical
Publication of JP6522619B2 publication Critical patent/JP6522619B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016538536A 2013-12-13 2014-12-11 医薬剤形 Active JP6522619B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915606P 2013-12-13 2013-12-13
US61/915,606 2013-12-13
PCT/IB2014/066820 WO2015087283A1 (en) 2013-12-13 2014-12-11 Pharmaceutical dosage forms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019082147A Division JP6804585B2 (ja) 2013-12-13 2019-04-23 医薬剤形

Publications (3)

Publication Number Publication Date
JP2017502941A JP2017502941A (ja) 2017-01-26
JP2017502941A5 true JP2017502941A5 (OSRAM) 2018-01-25
JP6522619B2 JP6522619B2 (ja) 2019-05-29

Family

ID=52146563

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016538536A Active JP6522619B2 (ja) 2013-12-13 2014-12-11 医薬剤形
JP2019082147A Active JP6804585B2 (ja) 2013-12-13 2019-04-23 医薬剤形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019082147A Active JP6804585B2 (ja) 2013-12-13 2019-04-23 医薬剤形

Country Status (33)

Country Link
US (3) US10278969B2 (OSRAM)
EP (2) EP3079667B1 (OSRAM)
JP (2) JP6522619B2 (OSRAM)
KR (1) KR102349893B1 (OSRAM)
CN (2) CN105813635A (OSRAM)
AR (1) AR098716A1 (OSRAM)
AU (1) AU2014362999B2 (OSRAM)
CA (1) CA2930055C (OSRAM)
CL (1) CL2016001436A1 (OSRAM)
CY (1) CY1122063T1 (OSRAM)
DK (1) DK3079667T3 (OSRAM)
EA (1) EA036288B1 (OSRAM)
EC (1) ECSP16060194A (OSRAM)
ES (1) ES2745983T3 (OSRAM)
HR (1) HRP20191691T1 (OSRAM)
HU (1) HUE045156T2 (OSRAM)
IL (1) IL245705B (OSRAM)
LT (1) LT3079667T (OSRAM)
MA (1) MA39175A1 (OSRAM)
MX (1) MX2016007652A (OSRAM)
MY (1) MY194303A (OSRAM)
NZ (2) NZ719865A (OSRAM)
PE (1) PE20160851A1 (OSRAM)
PH (1) PH12016501039B1 (OSRAM)
PL (1) PL3079667T3 (OSRAM)
PT (1) PT3079667T (OSRAM)
RS (1) RS59270B1 (OSRAM)
SG (1) SG10202104627UA (OSRAM)
SI (1) SI3079667T1 (OSRAM)
TN (1) TN2016000207A1 (OSRAM)
TW (2) TWI721938B (OSRAM)
WO (1) WO2015087283A1 (OSRAM)
ZA (1) ZA201603064B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014362999B2 (en) 2013-12-13 2017-10-12 Novartis Ag Pharmaceutical dosage forms
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
EP4262774A4 (en) * 2020-12-18 2024-11-13 QED Therapeutics, Inc. METHODS FOR TREATING ACHINDROPLASIA
CN117042738A (zh) * 2021-03-17 2023-11-10 埃科特莱茵药品有限公司 药物剂量系统

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CN101336237B (zh) 2005-12-21 2015-09-30 诺华股份有限公司 作为fgf抑制剂的嘧啶基芳基脲衍生物
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
ES2610931T3 (es) 2011-07-01 2017-05-04 Novartis Ag Terapia de combinación
AU2014287209B2 (en) 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
AU2014362999B2 (en) 2013-12-13 2017-10-12 Novartis Ag Pharmaceutical dosage forms
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
JP2018509448A (ja) 2015-03-25 2018-04-05 ノバルティス アーゲー 組合せ医薬
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors

Similar Documents

Publication Publication Date Title
TWI856111B (zh) 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法
JP2017502941A5 (OSRAM)
KR101977785B1 (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법
JP2007091758A5 (OSRAM)
JP6320371B2 (ja) エンテカビルの医薬組成物および製造方法
JP2016536285A (ja) アムロジピン及びバルサルタンを含む安定な医薬組成物
JP5614445B2 (ja) 経口投与用粒子状医薬組成物
JP2011500811A5 (OSRAM)
KR101171375B1 (ko) 난용성 약물을 함유하는 경구 제형
KR102349893B1 (ko) 제약 투여 형태
CN102846573B (zh) 水飞蓟宾双层缓释片及其制备方法
JP2013544272A5 (OSRAM)
JP2017520619A5 (OSRAM)
JP6379043B2 (ja) カンデサルタンシレキセチル含有医薬組成物
KR20100046216A (ko) 칸데사르탄의 약학 조성물
JP6883401B2 (ja) アジルサルタン含有錠剤及び錠剤におけるアジルサルタンの安定化方法
JP2016124861A (ja) オルメサルタンメドキソミル含有口腔内崩壊錠
CN112057427B (zh) 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
JP5680607B2 (ja) 安定固形製剤及びその製造法
CN101152155A (zh) 盐酸伊伐布雷定固体药物组合物及其制备方法
JP6176246B2 (ja) 固形医薬錠剤およびその製造方法
CN113768889B (zh) 一种含西洛他唑的药物组合物及其制备方法
WO2014122671A2 (en) Solid oral compositions of saxagliptin
CN104000821B (zh) 含有替米沙坦和苯磺酸氨氯地平的口服双层片剂及其制备方法
CN100551369C (zh) 一种含有西洛他唑的缓释制剂及其制备方法